PharmaEngine

PharmaEngine EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 5.34. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 20.18 — a change of -73.55% (lower).

EV/OCF

5.34

YoY

-73.55%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of PharmaEngine is 2025 5.34 . EV/OCF (Enterprise Value to Operating Cash Flow) of PharmaEngine was 2024 20.18 . It decreases by -73.55% lower compared to the previous year.

The PharmaEngine EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
7.45 TWD
Jan 1, 2019
362.90 TWD
Jan 1, 2020
90.25 TWD
Jan 1, 2021
5.82 TWD
Jan 1, 2022
27.61 TWD
Jan 1, 2023
21.81 TWD
Jan 1, 2024
20.18 TWD
Jan 1, 2025
5.34 TWD
The PharmaEngine EV/OCF history
YEAREV/OCFYoY
5.34-73.55%
20.18-7.46%
21.81-21.02%
27.61+374.42%
5.82-93.55%
90.25-75.13%
362.90+4,768.26%
7.45-142.58%
-17.51-387.02%
6.10-54.98%
13.55-71.91%
48.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EV/OCF (Enterprise Value to Operating Cash Flow) of PharmaEngine is 5.34 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of PharmaEngine changed from 20.18 to 5.34, representing a -73.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PharmaEngine

All Key Metrics — PharmaEngine